New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist
Dyslipidemia is one of the most significant modifiable cardiovascular risk factors. The change in the modern paradigm for dyslipidemia treatment from high-intensity statin therapy to high-intensity lipid-lowering therapy makes it possible to more often use new drug classes to achieve the target leve...
Main Authors: | A. B. Skiba, M. V. Menzorov, V. D. Puchek, I. M. Buchin, I. I. Polyakov, E. N. Menzorova |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2023-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2977 |
Similar Items
-
The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: a cost-effectiveness analysis
by: Wenjing Zhou, et al.
Published: (2024-02-01) -
Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
by: Laiba Imran Vohra, et al.
Published: (2023-07-01) -
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023-01-01) -
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
by: Yanzhen Zhang, et al.
Published: (2023-10-01) -
Assessment of the global and national market for lipid modifying agents: retrospective and innovation
by: A. V. Lokhmacheva, et al.
Published: (2023-08-01)